Ascletis Pharma's (HKG:1672) attributed losses in 2024 widened year on year to 300.9 million yuan or 0.3005 yuan per share from 144.7 million yuan or 0.1347 yuan per share, according to a Hong Kong Stock Exchange disclosure on Wednesday.
The biotechnology company's revenue plummeted to 1.3 million yuan from 56.6 million yuan a year earlier.
The company's shares closed 10% lower.